Alzheimer's Disease Trial, Recruiting (NCT05372172)

Alzheimer's Disease Trial, Recruiting NCT05372172 Sponsor: Vanderbilt University Medical Center Condition: Alzheimer's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05372172 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Alzheimers Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 60 or older
People who fall into one of three cognitive categories: no memory or thinking problems, mild memory or thinking problems, or an Alzheimer's disease diagnosis
People who speak English
People who are able to give their own informed consent to participate at the start of the study

Who may not be able to join:

People who do not have a reliable support person (such as a family member or close friend) who regularly spends time with them and is able to take part in study visits, either in person or by phone
People with a history of major psychiatric conditions (such as schizophrenia or bipolar disorder), neurological conditions (such as epilepsy, multiple sclerosis, or Parkinson's disease), or a significant head injury that resulted in a notable loss of consciousness
People who are unable to have an MRI scan, for example due to a fear of enclosed spaces or having certain metal implants in the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Angela Jefferson, PhD, Professor of Neurology

Phone: 615-875-3175

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05372172

Sponsor: Vanderbilt University Medical Center

Phase: Not Applicable

Status: Recruiting

Condition: Alzheimer's Disease

Trial contact: 615-875-3175

More information: https://clinicaltrials.gov/study/NCT05372172

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 60 or older
People who fall into one of three cognitive categories: no memory or thinking problems, mild memory or thinking problems, or an Alzheimer's disease diagnosis
People who speak English
People who are able to give their own informed consent to participate at the start of the study

Who may not be able to join:

People who do not have a reliable support person (such as a family member or close friend) who regularly spends time with them and is able to take part in study visits, either in person or by phone
People with a history of major psychiatric conditions (such as schizophrenia or bipolar disorder), neurological conditions (such as epilepsy, multiple sclerosis, or Parkinson's disease), or a significant head injury that resulted in a notable loss of consciousness
People who are unable to have an MRI scan, for example due to a fear of enclosed spaces or having certain metal implants in the body

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Vanderbilt University Medical Center

Registry

ClinicalTrials.gov

Start date

27 October 2021

Est. completion

31 March 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Cognitive status; APOE Genotype; White matter hyperintensities Volume; Grey Matter Volume; Cerebral Blood Flow; Lacunar infarcts; Microbleeds; Left ventricular ejection fraction; Cardiac output; Stroke volume; Heart rate; Biological markers for Alzheimer's disease; Blood based biological marker for Alzheimer's disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov